Drug testing supplies for treatment centers, intake through milestone monitoring.

Yes. Treatment census is rarely flat: admissions surge in January and after holidays, dip in summer at some programs, and intake-heavy weeks need extra stock. You can adjust your next shipment quantity up to 5 days before the shipment date through your account dashboard, or by emailing your account rep. Subscription pricing stays locked through quantity changes, so you don't lose the 15% by scaling.

Yes. Programs with sustained volume (250+ units/month) can specify custom panels, adding fentanyl analogs, kratom, buprenorphine (to differentiate MAT compliance from illicit use), and oxycodone-specific cutoffs separate from the broader opiate strip. Custom configurations require additional production lead time before shipment. We do not recommend custom panels for buprenorphine without a clinical workflow that distinguishes prescribed vs. illicit; you will get false-conflict positives.

We supply educational PDFs your alumni or family-program team can co-brand, covering how at-home tests work, why presumptive positives need confirmation, and what to do if a result comes back unexpected. We do not sell directly to families; that's your clinical relationship. ASC supplies the program, the program educates the family.

For court-ordered treatment, drug court, family-dependency court, and DUI/DWI programs, every test result needs court-defensible chain-of-custody documentation. Our COC forms and lot traceability are built to support that evidentiary standard, so when a milestone test moves to a contested hearing, the documentation is there to back it up.

Presumptive (point-of-care) testing is typically billed under CPT 80305 ("any number of drug classes"). Definitive (LC-MS-MS) confirmation testing runs at the lab under CPT codes in the 80320 to 80377 range depending on substance class. Behavioral health programs should verify medical-necessity criteria with each payer; some require documented clinical justification for testing frequency. ASC does not bill insurance for you, but our utilization reporting matches what auditors and payers ask to see.

Yes. MAT-aware panels include separate buprenorphine (BUP) and methadone (MTD) strips so you can distinguish prescribed medication from illicit opioid use. Without the BUP strip, your full-spectrum opiate panel will go negative on a buprenorphine-stable patient (buprenorphine doesn't cross-react with traditional opiate immunoassays), which can mask issues. Our MAT-focused panel adds BUP, MTD, and a fentanyl-specific strip alongside the broader opiate detection.

ASC retains lot, COA, and shipment records indefinitely, searchable via your account dashboard by date, lot, or order. That record depth is built to support accreditation (CARF, Joint Commission) and state licensing documentation requests. We do not store individual patient test results (that's your EMR), but the supply-side documentation needed to defend any historical specimen lives in our system indefinitely.